Company Overview: JUNO

Upcoming Projects (JUNO)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (JUNO)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (JUNO)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (JUNO)

Juno Therapeutics (JUNO) Highlights Data and Presentations for JCAR017 at ASH
Ticker: JUNO
Occurred on: Dec 12, 2017
FDA Designated Juno's JCAR017 a Breakthrough Therapy for the Treatment of Relapsed/Refractory Aggressive Large B-cell Non-Hodgkin Lymphoma (NHL), Including Diffuse Large B-Cell Lymphoma (DLBCL) and Certain Other Lymphomas
Ticker: JUNO
Occurred on: Dec 20, 2016
Juno Therapeutics (JUNO) Suspends Phase 2 ROCKET Study Assessing JCAR015 in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Tickers: JUNO, KITE, CLLS
Occurred on: Nov 23, 2016
JCAR014 Clinical Data Published in Science Translational Medicine: Patients with Advanced Lymphoma in Remission after T-cell Therapy
Ticker: JUNO
Occurred on: Sep 07, 2016
FDA has removed the clinical hold on the Phase II clinical trial of JCAR015 (known as the “ROCKET” trial) in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL)
Tickers: JUNO, CLLS, KITE, BLUE, ZIOP
Occurred on: Jul 12, 2016
Juno Therapeutics Reports Clinical Hold on the JCAR015 Phase II ROCKET Trial
Ticker: JUNO
Occurred on: Jul 07, 2016
Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability
Ticker: JUNO
Occurred on: Jun 04, 2016
Juno Therapeutics’ Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL
Ticker: JUNO
Occurred on: Jun 04, 2016
Complete Remission Rate of 90%: China-based CAR-T Cell Therapy Achieves Breakthrough Clinical Trial Results
Tickers: INNOVATIVE CELLULAR THERAPEUTICS, NVS, JUNO, KITE
Occurred on: May 06, 2016
Juno’s Investigational CAR T Cell Product Candidates JCAR018 and JTCR016 Demonstrate Encouraging Clinical Responses in Patients with B-Cell and Mesothelioma Cancers
Ticker: JUNO
Occurred on: Apr 20, 2016
Leukemia Research presented at American Association for the Advancement of Science (AAAS) leads to boost for CAR-T developers
Tickers: BLUE, KITE, CLLS, ZIOP, JUNO, BLCM, CYAD, ADAP
Occurred on: Feb 16, 2016
NIH study results of off-the-shelf CAR-Ts pose threat to designer CAR-T producers Kite Pharma (KITE) and Juno Therapeutics (JUNO)
Tickers: KITE, CLLS, JUNO
Occurred on: Jan 26, 2016

Strategic Initiatives (JUNO)

Juno Therapeutics Signs Licensing Agreement with Lilly to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition
Tickers: JUNO, LLY
Announcement Date: Dec 06, 2017
Novartis disbands its pioneering cell and gene therapy unit
Tickers: NVS, JUNO, KITE
Announcement Date: Aug 31, 2016
Juno Therapeutics, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center Announce New Immuno-oncology Clinical Trials Unit
Ticker: JUNO
Announcement Date: Feb 23, 2016

JUNO Overview